MapLight Therapeutics (MPLT) Cash from Operations (2024 - 2025)

MapLight Therapeutics recorded quarterly Cash from Operations of 46829000.0 in Q4 2025, down 117.93% quarter-over-quarter from 21488000.0 in Q4 2024, and down 117.93% year-over-year from 261163133.14 in Q4 2024.

MapLight Therapeutics' Cash from Operations history runs 2 years deep, the most recent figure standing at 46829000.0 for Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Operations (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -1.67 Mn
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn -12.20 Mn
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -2.49 Mn
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn 1.43 Bn
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn 1.08 Bn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn 70.50 Mn
10 MapLight Therapeutics 254.43 Mn 254.43 Mn - -46.83 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 -46.83 Mn
Dec 31, 2025 -46.83 Mn
Dec 31, 2024 -21.49 Mn
Dec 31, 2024 -21.49 Mn